Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
Authors' conclusion
SURPASS-CVOT will provide definitive evidence as to the CV safety and efficacy of tirzepatide as compared with dulaglutide, a GLP-1 receptor agonist with established CV benefit.
Study context
- Population
- People with T2DM aged ≥40 years with established atherosclerotic CVD, HbA1c ≥7% to ≤10.5% and BMI ≥25 kg/m²randomised
- Participants
- 13,299 people
- Comparison
- Tirzepatide vs dulaglutide
- Primary endpoint
- Time to first MACE:
- Cardiovascular (CV) death
- MI
- Stroke
Methodological detailsSURPASS-CVOT, double-blind, active-controlled, event-driven, non-inferiority, 1:1 randomisation, 640 sites in 30 countries
- SURPASS-CVOT
- Double-blind
- Active-controlled
- Event-driven
- Non-inferiority
- 1:1 randomisation
- 640 sites in 30 countries
Primary result
As reported in the abstract
Baseline characteristics · baseline
- Mean age
- 64.1 years
- Diabetes duration
- 14.7 years
- HbA1c
- 8.4%
- BMI
- 32.6 kg/m²
- Coronary disease
- 65.0%
- Prior MI (of those with coronary disease)
- 47.3%
- Prior coronary revascularization (of those with coronary disease)
- 57.4%
- Prior stroke
- 19.1%
- PAD
- 25.3%
Original publication
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics. Am Heart J. Published 25 September 2023. doi:10.
Summarised from the published abstract; every number is checked against it